Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors

PHASE2CompletedINTERVENTIONAL
Enrollment

290

Participants

Timeline

Start Date

August 1, 2014

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Autism Spectrum Disorders
Interventions
DRUG

Double blind phase Placebo Nasal Spray

This nasal spray will contain all of the ingredients that are in the active oxytocin spray in the same quantities, except oxytocin will NOT be added to the solution. It will be packaged using the same container system as the active oxytocin nasal spray. Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. Dose titration will occur using exactly the same criteria and procedures as for active study drug.

DRUG

double Blind Oxytocin Nasal Spray

Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and weeks 4 and 8 until achieving the target dose of 24 IU BID at week 8. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.Each bottle's label will have its own unique nonsequential randomly assigned number and not a lot number to facilitate masking. During the open label phase after approximately March 2019 the study used only the 24 IU /0.10 ml formulation and the maximum dose was 72 IU per day.

DRUG

Open Label intranasal oxytocin

All participants who completed the 24 week double blind phase were eligible to join a 24 week open label phase in which all participants received intranasal oxytocin

Trial Locations (7)

10029

Mount Sinai School of Medicine, New York

10605

Center for Autism and the Developing Brain, White Plains

27705

Duke Center for Autism and Brain Development, Durham

27710

Duke University , Genetics Center, Durham

37212

Vanderbilt University, Nashville

98105

Seattle Children's Hospital Research Institute, Seattle

02114

Lurie Center for Autism, Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Linmarie Sikich

OTHER

NCT01944046 - Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors | Biotech Hunter | Biotech Hunter